Obesity Medicine

Use of GLP-1 receptor agonists for weight loss has more than doubled since early 2024 while 7.6 million fewer US adults qualify as obese in 2025.

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

Obesity rates in states where it has leveled at 35% decreased for the first time but report authors warn the progress is limited and at risk due to federal budget cuts.

New research reveals GLP-1 receptor agonists may alter PET-CT scan interpretations, highlighting the need for updated guidelines in oncological imaging.

Semaglutide and tirzepatide "should be first-line treatment" for people with obesity and its myriad of complications, says EU obesity professional association.

Novo Nordisk aims to revolutionize diabetes care with its resubmission for insulin icodec, a potential first once-weekly basal insulin for type 2 diabetes therapy in adults.

Your daily dose of the clinical news you may have missed.

Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.

Your daily dose of the clinical news you may have missed.

EASD 2025. A new oral GLP-1 receptor agonist, orforglipron, shows promise for significant weight loss and improved cardiometabolic health in adults with obesity.

EASD 2025: After initiating treatment with semaglutide, the number of people who reported experiencing constant thoughts about food throughout the day declined by 46%.

EASD 2025: Findings from a subanalysis of the REDEFINE 1 phase 3 trial support Novo Nordisk's plan to advance cagrilintide into a dedicated clinical program this year.

Your daily dose of the clinical news you may have missed.

Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.

With the surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

Your daily dose of the clinical news you may have missed.

Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

In a trial of over 112 000 US adults, researchers found that 14% started a GLP-1 receptor agonist after bariatric surgery.